Production (Stage)
Cue Biopharma, Inc.
CUE
$0.602
-$0.0337-5.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -75.48% | -13.45% | 58.86% | 92.33% | 818.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -75.48% | -13.45% | 58.86% | 92.33% | 818.18% |
| Cost of Revenue | -17.77% | -27.46% | -5.49% | -10.52% | -0.98% |
| Gross Profit | 4.70% | 29.64% | 25.15% | 25.85% | 17.62% |
| SG&A Expenses | -0.26% | -29.27% | -17.12% | -17.37% | 21.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.57% | -27.69% | -9.40% | -12.47% | 6.03% |
| Operating Income | 2.91% | 29.59% | 21.95% | 23.19% | 5.32% |
| Income Before Tax | 0.73% | 29.31% | 21.31% | 22.86% | 5.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.73% | 29.31% | 21.31% | 22.86% | 5.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.73% | 29.31% | 21.31% | 22.86% | 5.81% |
| EBIT | 2.91% | 29.59% | 21.95% | 23.19% | 5.32% |
| EBITDA | 2.95% | 29.72% | 21.95% | 23.14% | 4.80% |
| EPS Basic | 33.85% | 55.06% | 28.81% | 31.12% | 14.99% |
| Normalized Basic EPS | 33.85% | 54.55% | 28.03% | 31.10% | 14.99% |
| EPS Diluted | 33.85% | 55.06% | 28.81% | 31.12% | 14.99% |
| Normalized Diluted EPS | 33.85% | 54.55% | 28.03% | 31.10% | 14.99% |
| Average Basic Shares Outstanding | 50.11% | 57.30% | 10.51% | 12.00% | 10.78% |
| Average Diluted Shares Outstanding | 50.11% | 57.30% | 10.51% | 12.00% | 10.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |